Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 recombinant protein vaccine
- Development stage
- Approved
- Lead developer
- Novavax
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
COVID-19 recombinant protein vaccines are a class of protein subunit vaccines designed to prevent COVID-19 by presenting a laboratory-engineered version of the SARS-CoV-2 spike protein to the immune system. Unlike mRNA or viral vector vaccines, these products deliver the antigen directly, typically in combination with an adjuvant (such as Novavax's Matrix-M or Sanofi's AS03) to enhance immunogenicity. This technology is used in authorized vaccines like Nuvaxovid (Novavax) and VidPrevtyn Beta (Sanofi/GSK). In clinical research, such as studies conducted by the Finnish Institute for Health and Welfare (THL), the term is used to categorize these authorized biologics when evaluating real-world immune responses and vaccine effectiveness against SARS-CoV-2 variants.
- Brand names
- NuvaxovidCovovaxVidPrevtyn BetaSKYCovione
- Other names
- SARS-CoV-2 recombinant protein vaccineSARS-CoV2 recombinant protein vaccineSARS-CoV 2 recombinant protein vaccineCOVID-19 protein subunit vaccineCOVID19 protein subunit vaccineCOVID 19 protein subunit vaccine
02
Targets
BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)
Beyond the preview
Go deeper on COVID-19 recombinant protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 recombinant protein vaccine.